Anupam Rasayan India Q4 FY26 results (Jan–Mar 2026) and concall

Chemicals · Concall AI · Call held 25 May 2026

Company page: Anupam Rasayan India share price, financials & guidance record

Anupam Rasayan reported a landmark FY26 with its highest ever revenue of INR2,384 crores, a 65% YoY increase, and a significant rise in PAT to INR222 crores. The company strategically expanded its portfolio through the acquisition of Jayhawk Fine Chemicals and a definitive agreement to acquire a controlling stake in Bliss GVS Pharma, aiming to build an integrated global life science and specialty pharmaceutical platform. While Q4 FY26 saw a slight dip in EBITDA and PAT compared to Q4 FY25, management expressed confidence in future growth driven by diversified revenue streams and synergistic ac

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q4 FY26: revenue up 27.2%, net profit down 11.1% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26
Revenue	294	390	500	486	731 +149%	512 +31%	636 +27%
Expenses	214	266	356	362	596	385	498
EBITDA	80	124	144	124	136 +70%	127 +2%	137 −5%
Margin	27%	32%	29%	26%	19%	25%	22%
Other income	2	-4	6	5	8	2	3
Interest	27	32	31	36	36	35	42
Depreciation	22	29	31	31	32	34	43
Profit before tax	34	59	88	63	76 +124%	60 +2%	56 −36%
Tax rate	10%	9%	29%	23%	24%	-1%	0%
Net profit	31	54	63	48	57 +84%	61 +13%	56 −11%
EPS	1.52	2.56	4.05	3.10	3.90	4.31	3.75

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Chemicals earnings calls